Dalsiclear 60mg Tablet (Daclatasvir 60 mg)

Dalsiclear 60mg Tablet is an antiviral medicine. It is prescribed to treat chronic hepatitis C virus (HCV) infection. It contains daclatasvir as an active ingredient. This tablet works by reducing the load of hepatitis C virus in the body and eliminating the virus from the blood over time. It should be taken in doses and durations as advised by the doctor. Don't take more than the recommended dose.

Hepatitis C

Dalsiclear 60mg Tablet(Daclatasvir 60 mg) is a strong antiviral medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.

Some common side effects of Dalsiclear 60mg include:
● Fatigue
● Headache
● Nausea
● Insomnia (difficulty sleeping)
● Anemia (low number of red blood cells)

The doctor determines the dosage and duration of the Dalsiclear 60mg Tablet (Daclatasvir 60 mg) as per the severity of the infection as well as the age & overall health condition of the patients. Swallow it as a whole with water and don't chew, crush or break the tablet.

This tablet may be taken with or without food. In case of an overdose of this tablet, contact your doctor or any healthcare provider and seek medical attention immediately.

● Eley, T., Sevinsky, H., Huang, S. P., He, B., Zhu, K., Kandoussi, H., ... & Bifano, M. (2014). The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus. Clinical drug investigation, 34(9), 661-671.
● Gamal, N., Gitto, S., & Andreone, P. (2016). Efficacy and safety of daclatasvir in hepatitis C: an overview. Journal of Clinical and Translational Hepatology, 4(4), 336.
● Garimella, T., You, X., Wang, R., Huang, S. P., Kandoussi, H., Bifano, M., ... & Eley, T. (2016). A review of daclatasvir drug–drug interactions. Advances in therapy, 33(11), 1867-1884.
● Bunchorntavakul, C., & Reddy, K. R. (2015). The efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Alimentary pharmacology & therapeutics, 42(3), 258-272.
● Gandhi, Y., Eley, T., Fura, A., Li, W., Bertz, R. J., & Garimella, T. (2018). Daclatasvir: a review of preclinical and clinical pharmacokinetics. Clinical pharmacokinetics, 57(8), 911-928.